-+ 0.00%
-+ 0.00%
-+ 0.00%

Soufflé Therapeutics closes oversubscribed $135 million Series B backed by Safar Partners

PUBT·10/13/2026 17:06:19
Listen to the news
Soufflé Therapeutics closes oversubscribed $135 million Series B backed by Safar Partners
  • Soufflé Therapeutics closed an oversubscribed Series B financing of $135 million on Oct. 13, 2026.
  • Safar Partners LLC participated as an existing investor in the round.
  • Soufflé is an RNA therapies company developing cell-specific delivery technology for targeted medicines.
  • Funds will advance three lead programs into clinical studies, including candidates for FSHD and heart failure with reduced ejection fraction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Safar Partners LLC published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.